First detection of Monkeypox virus genome in sewersheds in France

Wurtzer, Sébastien; Levert, Morgane; Dhenain, Eloïse; Boni, Mickaël; Tournier, Jean-Nicolas; Londinsky, Nicolas; Lefranc, Agnès; Ferraris, Olivier; Moulin, Laurent

doi:10.1101/2022.08.18.22278938

Cited by 3 publications

(1 citation statement)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is an alternative pathway for the production of EEV. It has been reported that the virion morphogenesis process in the prototype VACV can go awry, leading to the formation of dense particles that are not infectious [121]. However, this behavior has not been observed in MPXV [122].…”

Section: Genome Organization Replication Cycle and Morphologymentioning

confidence: 99%

An Updated Review on Monkeypox Viral Disease: Emphasis on Genomic Diversity

Rabaan,

Alasiri,

Aljeldah

et al. 2023

Biomedicines

View full text Add to dashboard Cite

Monkeypox virus has remained the most virulent poxvirus since the elimination of smallpox approximately 41 years ago, with distribution mostly in Central and West Africa. Monkeypox (Mpox) in humans is a zoonotically transferred disease that results in a smallpox-like disease. It was first diagnosed in 1970 in the Democratic Republic of the Congo (DRC), and the disease has spread over West and Central Africa. The purpose of this review was to give an up-to-date, thorough, and timely overview on the genomic diversity and evolution of a re-emerging infectious disease. The genetic profile of Mpox may also be helpful in targeting new therapeutic options based on genes, mutations, and phylogeny. Mpox has become a major threat to global health security, necessitating a quick response by virologists, veterinarians, public health professionals, doctors, and researchers to create high-efficiency diagnostic tests, vaccinations, antivirals, and other infection control techniques. The emergence of epidemics outside of Africa emphasizes the disease’s global significance. Increased monitoring and identification of Mpox cases are critical tools for obtaining a better knowledge of the ever-changing epidemiology of this disease.

show abstract

Section: Genome Organization Replication Cycle and Morphologymentioning

confidence: 99%

An Updated Review on Monkeypox Viral Disease: Emphasis on Genomic Diversity

Rabaan,

Alasiri,

Aljeldah

et al. 2023

Biomedicines

View full text Add to dashboard Cite

show abstract

Monkeypox in Europe: Epidemiology and Risk Factors – A Scoping Review Study

Ravichandran,

Jalili

2024

Preprint

View full text Add to dashboard Cite

Background Monkeypox (mpox) is a zoonotic disease originating from the Congo Basin (Clade I) and West Africa (Clade II). In 2022, mpox spread to non-endemic European countries, predominantly through human transmission associated with sexual contact. The outbreak in Europe was primarily with the Clade IIb lineage, which is less virulent. The World Health Organization (WHO) declared this outbreak a Public Health Emergency of International Concern (PHEIC) in 2022, which ended in May 2023 after a decline in cases. However, in July 2024, a resurgence of the more virulent Clade I occurred in the Democratic Republic of Congo (DRC), leading WHO to declare mpox a PHEIC again, due to the risk of global spread. Understanding epidemiology and risk factors of mpox is vital for effective public health measures. Methodology and principal findings A search conducted from 2014 to 2024 across PubMed, Scopus and Embase identified 46 studies on mpox in Europe, which were included for qualitative analysis. The key themes identified were epidemiology, risk factors, and implications for public health actions. High-risk behaviors include sexual contact among men who have sex with men (MSM) with multiple partners, living with HIV, and frequent travel to endemic regions. Conclusions and significance With no definitive cure for mpox, public health measures such as surveillance, monitoring, and contact tracing are essential. Additionally, encouraging case-control studies is crucial for exploring other potential risk behaviors and design behavioral interventions, vaccination campaigns and awareness programs aimed at reducing high-risk behaviors among these populations. Although the number of cases in Europe did not surge in August 2024, proactive measures are necessary to prevent further spread.

show abstract

An evaluation of the preprints produced at the beginning of the 2022 mpox public health emergency

Sterian,

Samra,

Pussegoda

et al. 2024

Res Integr Peer Rev

View full text Add to dashboard Cite

Background Preprints are scientific articles that have not undergone the peer-review process. They allow the latest evidence to be rapidly shared, however it is unclear whether they can be confidently used for decision-making during a public health emergency. This study aimed to compare the data and quality of preprints released during the first four months of the 2022 mpox outbreak to their published versions. Methods Eligible preprints (n = 76) posted between May to August 2022 were identified through an established mpox literature database and followed to July 2024 for changes in publication status. Quality of preprints and published studies was assessed by two independent reviewers to evaluate changes in quality, using validated tools that were available for the study design (n = 33). Tools included the Newcastle-Ottawa Scale; Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2); and JBI Critical Appraisal Checklists. The questions in each tool led to an overall quality assessment of high quality (no concerns with study design, conduct, and/or analysis), moderate quality (minor concerns) or low quality (several concerns). Changes in data (e.g. methods, outcomes, results) for preprint-published pairs (n = 60) were assessed by one reviewer and verified by a second. Results Preprints and published versions that could be evaluated for quality (n = 25 pairs) were mostly assessed as low quality. Minimal to no change in quality from preprint to published was identified: all observational studies (10/10), most case series (6/7) and all surveillance data analyses (3/3) had no change in overall quality, while some diagnostic test accuracy studies (3/5) improved or worsened their quality assessment scores. Among all pairs (n = 60), outcomes were often added in the published version (58%) and less commonly removed (18%). Numerical results changed from preprint to published in 53% of studies, however most of these studies (22/32) had changes that were minor and did not impact main conclusions of the study. Conclusions This study suggests the minimal changes in quality, results and main conclusions from preprint to published versions supports the use of preprints, and the use of the same critical evaluation tools on preprints as applied to published studies, in decision-making during a public health emergency.

show abstract

First detection of Monkeypox virus genome in sewersheds in France

Cited by 3 publications

References 21 publications

An Updated Review on Monkeypox Viral Disease: Emphasis on Genomic Diversity

An Updated Review on Monkeypox Viral Disease: Emphasis on Genomic Diversity

Monkeypox in Europe: Epidemiology and Risk Factors – A Scoping Review Study

An evaluation of the preprints produced at the beginning of the 2022 mpox public health emergency

Contact Info

Product

Resources

About